Biofidus AG is now a member of the Midas Group

With the acquisition of Biofidus, a leading provider of structural and functional characterization of biopharmaceuticals, Midas Pharma has taken a major step forward in expanding its portfolio of biopharmaceutical services.

With this merger, the companies expand their portfolios of service solutions, offering seamless and modular support for the entire pharmaceutical value chain – from discovery to commercialization.  

Joining forces provides new opportunities for future growth, innovation, and shared success. As key part of their mutual growth strategy, the companies are implementing a GMP environment at Biofidus to further expand their analytical capabilities.